Table 2.
Descriptive data of the population
| Variable | Patients’ Groupa n (%) |
Healthy donors’ Group (%) (n = 30) | ||
|---|---|---|---|---|
| Sex | Female | 5 (29.4) | 7 (23.4) | |
| Male | 12 (70.6) | 23 (76.6) | ||
| Age (years) | Mean | 61.8 | 63.5 | |
| Range | (34–90) | (33–82) | ||
| Tumour stageb (Borrmann classification) | I | 0 | Does not apply | |
| II | 5 (38.4) | |||
| III | 4 (30.8) | |||
| IV | 4 (30.8) | |||
| Tumour typeb (Lauren classification) | Intestinal-type | Poorly differentiated | 3 (23.0) | |
| Moderately differentiated | 3 (23.0) | |||
| Well differentiated | 3 (23.0) | |||
| Diffuse | 1 (8.0) | |||
| Not specified | 3 (23.0) | |||
| Metastasisb | None | 7 (53.8) | ||
| Lymphoid nodules (only) | 0 | |||
| Other organs | 5 (38.5) | |||
| Both | 1 (7.7) | |||
| Clinical evolutionb (Four years later) | Remission (alive) | 7 (53.8) | ||
| Deceased | 6 (46.2) | |||
| Survival Post diagnosisb,g Average (range, months) | IL-4 low levelb,c | Overall | 6 (46.2); 33.2 (1–47) | |
| Deceased (only) | 2 (33.3)d; 13.5 (1–26) | |||
| IL-4 high levelb,e | Overall | 7 (53.8); 26.4 (10–48) | ||
| Deceased (only) | 4 (57.1)f; 13.0 (10–18) | |||
| Absence of IL-10 -1082 (G/A) SNPg | Overall | 4 (40); 38.8 (26–42) | ||
| Deceased (only) | 1 (25)h; 26.0 | |||
| Presence of IL-10 -1082 (G/A) SNP Homozygous or Heterozygousg |
Overall | 6 (60); 21.7 (1–47) | ||
| Deceased (only) | 4 (66.7)i; 10.3 (1–18) | |||
aCases with data, n = 17; b Cases with data, n = 13. Data on patients not provided are subject to Institutional policies in keeping with National Legislation on Habeas data); c Less than 5 pg/mL; d Regarding the totality of patients with low level of IL-4; e Greater than 5 pg/mL (all cases above 12 pg/mL); f Regarding the totality of patients with high level of IL-4; g n = 10 (three cases showed no amplification band); h Regarding the totality of patients with Absence of IL-10 -1082 (G/A) SNP; i Regarding the totality of patients with Presence of IL-10 -1082 (G/A) SNP